Kayne Richard A's Form 4 filing
Eiger BioPharmaceuticals, Inc. (EIGR) · filed Nov 2, 2023
- Accession no.
- 0001140361-23-051263
- Filed
- Nov 2, 2023, 9:21 PM ET
- Trade date
- Oct 31-Nov 2, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market purchases total $72.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kayne Richard ACIK 0000884413 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 31, 2023 | Common Stock | PPurchaseAcquired | +11,987 | $0.2625 | +$3,146.59 | 5,108,973 | Indirect | |
| Oct 31, 2023 | Common Stock | PPurchaseAcquired | +12,345 | $0.2615 | +$3,228.22 | 5,121,318 | Indirect | |
| Oct 31, 2023 | Common Stock | PPurchaseAcquired | +130,509 | $0.2414 | +$31,504.87 | 5,251,827 | Indirect | |
| Nov 1, 2023 | Common Stock | PPurchaseAcquired | +100,000 | $0.2797 | +$27,970 | 5,351,827 | Indirect | |
| Nov 2, 2023 | Common Stock | PPurchaseAcquired | +23,398 | $0.2977 | +$6,965.58 | 5,375,225 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.